Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Mr. David J. Topper

Senior Vice President & Chief Financial Officer

Ms. Amanda  Sheldon

Head of Corporate Communications

Mr. L. Todd Edwards

Senior Vice President & Chief Commercial Officer

Mr. Masaru  Matsuda Esq., J.D.

Senior Vice President, General Counsel & Corporate Secretary

Mr. Rajvir  Madan

Chief Digital & Technology Officer

Ms. Latha  Vairavan

Vice President of Finance & Investor Relations

Ms. Courtney  Barton

Vice President and Chief Compliance Officer & Privacy Officer

Mr. Todd Franklin Watanabe M.A.

President, Chief Executive Officer & Director

Dr. Patrick E. Burnett M.D., Ph.D.

Senior Vice President & Chief Medical Officer

Dr. Bhaskar  Chaudhuri Ph.D.

Co-Founder & Independent Director

Biotechnologie

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. Structuur van het management

Informatie over het management